Bloomberg Brief: Hedge Funds ACTIVIST
Total Page:16
File Type:pdf, Size:1020Kb
Load more
Recommended publications
-
20170308 Item 10.Pdf
Memorandum To Water & Power Employees’ Retirement Plan (“The Plan”) From RVK, Inc. (“RVK”) Subject Custom FoHF Finalist Recommendation Date February 23, 2017 Recommendation After reviewing the RFP responses for the custom Fund of Hedges Funds RFP, Plan Staff and RVK recommend that the Board interview the following finalist candidates: • BlackRock, Inc. • Blackstone Alternative Asset Management • Goldman Sachs Asset Management • Grosvenor Capital Management Background The Plan and RVK launched a Request for Proposal (“RFP”) for custom Fund of Hedge Fund mandate in the fourth quarter of 2016. Respondents were required to complete the RFP by October 24, 2016. The following minimum qualifications (“MQs”) were used to initially reduce the universe to a list of appropriate candidates. 1. Offeror must have at least $7.5 billion in discretionary assets under management in institutional multi-strategy fund of hedge fund portfolios. 2. Offeror must have at least ten years of experience managing discretionary, multi- strategy Hedge Fund of One portfolios and include this performance history in the proposal 3. Offeror must certify in writing that it will act as a fiduciary when performing these services and be bound by Prudent Investor Rule standards. 4. Offeror must be an investment advisor registered with the SEC or otherwise exempt from registration. If exempt, the Manager must explain the nature of their exemption from registration. (Form ADV, Parts 1 and 2, must be submitted). 5. The Offeror must comply with City of Los Angeles and the Los Angeles Department of Water and Power requirements 6. The successful Offeror must agree to obtain a City of Los Angeles Business Tax Registration Certificate. -
A Look at the Legality Behind Daraprim's Price Spike Law360, New York (September 30, 2015, 12:15 PM ET)
Portfolio Media. Inc. | 860 Broadway, 6th Floor | New York, NY 10003 | www.law360.com Phone: +1 646 783 7100 | Fax: +1 646 783 7161 | [email protected] A Look At The Legality Behind Daraprim's Price Spike Law360, New York (September 30, 2015, 12:15 PM ET) -- Turing Pharmaceuticals AG and its controversial CEO Martin Shkreli recently made headlines when Turing raised the price of its antiprotozal drug Daraprim (pyrimethamine) from $13.50 to $750 per tablet.[1] The price increase received significant media attention. Here, we evaluate Turing’s Daraprim price hike from a legal perspective, including an analysis of the mechanisms used to balance innovation and drug pricing in the U.S., and their degree of application, if any, to the drug’s recent price hike. Balancing Drug Prices and Innovation The United States has traditionally incentivized drug development innovation. Charles J. Andres Patents and the U.S. Food and Drug Administration's regulatory exclusivities allow an innovator to enjoy a protected U.S. market for a finite period of time. The market protection provided by these exclusivities helps innovators to recoup their research costs and make profits which, in part, are used to fund new research. Conversely, after the expiration of patents and market exclusivities, generic drugs can enter the marketplace. Generic drugs can ultimately cost 80 percent less than the branded drug.[2] Accordingly, U.S. laws (e.g., the Hatch-Waxman Act and Biologic Price Competition and Innovation Act of 2009) attempt to strike a balance by providing market incentives to innovators to bring new medicines to market in exchange for making generic drugs available to patients at a greatly reduced cost. -
Notorious Turing CEO Martin Shkreli Arrested for Securities Fraud Like Share Tweet Share
Job Seeker: Login Sign Up Employer: Login Post Jobs HOME NEWS JOBS CAREER RESOURCES HOTBEDS CAREER FAIRS EVENTS COMPANY PROFILES INVESTORS Search Life Sciences Jobs Job Title, Keyword or Company Name City, State, or Postal Code FIND JOBS > News | News By Subject | News by Disease | News By Date | Search News Get Our FREE Industry eNewsletter email: Notorious Turing CEO Martin Shkreli Arrested for Securities Fraud Like Share Tweet Share 12/17/2015 6:20:27 AM December 17, 2015 By Alex Keown, BioSpace.com Breaking News Staff NEW YORK – Martin Shkreli, the pharmaceutical industry’s so-called “bad boy,” has been arrested on charges of securities fraud related to his tenure as chief executive officer of Retrophin Inc. (RTRX) Shkreli, who became something of an industry pariah after increasing the price of a 65-year-old drug 5,000 percent, then lamenting the fact that he didn’t raise it even higher in order to increase profit, was arrested at his home this morning, Bloomberg reported. Shkreli is being charged with a misuse of company funds when he was CEO of that company. Prosecutors allege that Shkreli took company stock and used it to pay off personal debts. Additionally, Shkreli is charged with playing shell games with his former hedge fund, MSMB Capital Management, which lost millions of investor’s dollars, Bloomberg said. In January, Shkreli came under investigation by U.S. prosecutors for possible securities violations and from the U.S. Securities and Exchange Commission for the distribution of stock without letting shareholders know. An internal probe conducted by Retrophin and filed with the Securities and Exchange Commission on Feb. -
Global Macro–Why Now?
Global Macro–Why Now? SOLUTIONS & MULTI ASSET | AIP HEDGE FUND TEAM | INVESTMENT INSIGHT | 2018 Global Macro is an investment CO-AUTHORS style that is highly opportunistic and has the potential to generate MARK VAN DER ZWAN, CFA strong risk-adjusted returns in Chief Investment Officer challenging markets. Against a backdrop and Head of AIP Hedge Fund Team of geopolitical uncertainty and potentially increased volatility,1 we felt it would be timely to share our insights on the space and explain ROBERT RAFTER, CFA Head of Discretionary Global why we believe now could be an opportune Macro, Sovereign Fixed time to make an allocation to Global Macro. Income Relative Value and Emerging Markets Strategies Both equity and fixed income markets have exhibited strong performance in recent years, leading to fully valued stock markets, historically low yields and tight credit spreads. However, substantial U.S. fiscal stimulus through a $1.5 trillion tax cut and a $300 billion increase in government spending,2 amid robust economic growth and inflation readings, have made it difficult for investors to adopt a more cautious, late- cycle posture in their portfolios. Importantly, increasing market volatility levels may result from any of a litany of potential catalysts, including escalating protectionist policies, U.S. midterm elections, central bank policy missteps, Italian debt sustainability, tensions in the Middle East, and political unrest in key emerging markets. We believe that these dynamics have 1 Please see Glossary for definitions. 2 Source: AIP Hedge Fund Team. The statements above reflect the opinions and views of Morgan Stanley Investment Management as of the date hereof and not as of any future date and will not be updated or supplemented. -
Attorney General Herring Files Suit Against Martin
SSearch Search ... Commonwealth of Virginia Office of the Attorney General Mark Herring 202 North Ninth Street Attorney General Richmond, Virginia 23219 For media inquiries only, contact: Charlotte Gomer, Press Secretary Phone: (804)786-1022 Mobile: (804) 512-2552 Email: [email protected] ATTORNEY GENERAL HERRING FILES SUIT AGAINST MARTIN SHKRELI AND VYERA PHARMACEUTICALS ~ Lawsuit seeks repayment of illegally obtained profits, lifetime ban on Shkreli working in pharmaceutical industry ~ RICHMOND (April 14, 2020) – Attorney General Mark R. Herring today joined a multistate lawsuit filed earlier this year against Vyera Pharmaceuticals, previously Turing Pharmaceuticals, and two of its former CEOs, including Martin Shkreli, for stifling competition to protect the exorbitant, monopolistic pricing of the drug Daraprim. Daraprim (pyrimethamine) is used to treat the parasitic disease toxoplasmosis, and despite Vyera Pharmaceuticals being the only FDA-approved source of the medication, Shkreli and Vyera raised the price of the drug by more than 4,000 percent overnight to $750 per pill, after purchasing the rights to Daraprim in August 2015. “Vyera Pharmaceuticals and Martin Shkreli made unconscionable decisions to maintain their monopoly on Daraprim and make as much money as possible,” said Attorney General Herring. “Because of their greed, Americans who couldn’t afford the exorbitant price of this drug were forced to make difficult, potentially life- threatening treatment decisions. Drug companies and their executives must be held accountable when they place profits over human lives.” Attorney General Herrring is one of six attorneys general today joining the lawsuit against Vyera and Shkreli that was originally filed by New York Attorney General Letitia James and the Federal Trade Commission (FTC) in January. -
Outline of Selected SEC Enforcement Actions, Division of Enforcement (October 2016)
© Practising Law Institute CORPORATE LAW AND PRACTICE Course Handbook Series Number B-2303 The SEC Speaks in 2017 Co-Chairs David W. Grim Marc Wyatt To order this book, call (800) 260-4PLI or fax us at (800) 321-0093. Ask our Customer Service Department for PLI Order Number 186008, Dept. BAV5. Practising Law Institute 1177 Avenue of the Americas New York, New York 10036 © Practising Law Institute Enforcement Panel and Workshop 41 © Practising Law Institute 42 © Practising Law Institute 3 Outline of Selected SEC Enforcement Actions, Division of Enforcement (October 2016) Prepared by: Sherry A. Peyton Research Specialist Seth Groveunder Intern The SEC (SEC), as a matter of policy, disclaims responsibility for any private publication or statement by any of its employees. The views expressed herein are those of the authors and do not necessarily reflect the views of the SEC or of the authors’ colleagues upon the staff of the SEC. Parts of this outline have been used in other publications. If you find this article helpful, you can learn more about the subject by going to www.pli.edu to view the on demand program or segment for which it was written. 43 © Practising Law Institute 44 © Practising Law Institute Table of Contents ACTIONS INVOLVING BROKER-DEALERS, INVESTMENT ADVISERS AND INVESTMENT COMPANIES AND OTHER REGULATED ENTITIES ......................................................................... 9 In the Matter of Merrill Lynch, Pierce, Fenner & Smith Incorporated ........................................................................................ 11 In the Matter of Merrill Lynch, Pierce, Fenner & Smith Incorporated Professional Clearing Corp. ........................................... 13 In the Matter of William Tirrell ............................................................. 15 SEC v. Ash Narayan, et al. ................................................................. 19 In the Matter of Apex Fund Services (US), Inc. -
David Walter Joined Double Haven As Head of Client Solutions from PAAMCO
David Walter joined Double Haven as Head of Client Solutions from PAAMCO Hong Kong – May 2, 2018. We are pleased to announce that David Walter has joined Double Haven Capital (Hong Kong) Limited in the position of Head of Client Solutions. David joins Double Haven from PAAMCO (one of the world’s leading institutional Fund of Hedge Funds) where he was a Director based in Asia. He has been involved in the Asian Hedge Fund Industry for over twenty years both as an allocator and through working with major institutional investors all over the world. Going forward, David will be leading the Firm’s fund raising strategy, and we are excited to bring David’s extensive knowledge, experience and market presence to the Firm. Darryl Flint, Double Haven’s Founder and CIO, adds: “This is a notable achievement for us to be able to bring a person with David’s experience and market standing into our team, and we look forward to the new direction that the Firm’s marketing effort will take under his stewardship.” David Walter Introduction David Walter joins the Double Haven team from April 2018 and is responsible for all client facing activities within the firm as well as the development of new products tailored to clients’ needs. He has been in the hedge fund industry for over 20 years and investing in Asia for over 30 years. Most recently he was a director at PAAMCO in Singapore, where he was responsible for the business development of the Firm’s Asian portfolios on a global basis and for sourcing and implementing investment ideas across Asia in multiple asset classes. -
Ex-Commonwealth PM Set to Launch $500M Macro Fund LAUNCH
The long and the short of it www.hfmweek.com ISSUE 497 3 MAY 2018 INFRAHEDGE CEO BRUCE KEITH DEPARTS AFTER 7 YEARS HFM EUROPEAN 2018 $30bn MAP co-founder to be replaced by Andrew Allright PEOPLE MOVES 03 PERFORMANCE AWARDS DEUTSCHE PUTS PRIME FINANCE BUSINESS UNDER REVIEW HF head Tarun Nagpal to leave bank after 15 years PRIME BROKERAGE 07 EX-GRUSS CAPITAL PROS PREP EVENT-DRIVEN FUND HFMWEEK REVEALS ALL Indar Capital expected to launch later this year LAUNCHES 10 THE WINNERS AWARDS 23 Ex-CommonWealth PM set to launch $500m macro fund Christopher Wheeler readies between 2013 and 2016. London-based CJW Capital CommonWealth closed BY SAM MACDONALD down last year as Fisher depart- ed to join $26bn Soros Fund FORMER CITADEL AND Management. CommonWealth Opportunity From November 2016 until Capital portfolio manager Chris- March this year, Wheeler is topher Wheeler is set to launch a understood to have traded a sub- LAUNCH macro fund with at least $500m stantial macro sleeve for Citadel. initial investment, HFMWeek He previously spent five years has learned. with London-based liquid multi- ANALYSIS Wheeler is starting London- asset business Talisman Global NUMBERS SURGE IN 2017 based CJW Capital Management Asset Management. He earlier with backing from a large asset worked at Morgan Stanley. manager and is looking to begin CJW Capital could become trading this year, HFMWeek one of this year’s largest HFM Global’s annual survey shows understands. European start-ups, amid a num- He registered the firm with ber of prominent macro hedge equity strategies remained most in UK Companies House on 23 fund launches. -
A Hard Day's Knight: the Global Financial Market Confronts
GLOBAL PERSPECTIVE S A Hard Day’s Knight: The Global Financial Market Confronts Uncertainty, Not Just Risk (and the Difference is Important) October 2007 Richard H. Clarida Global Strategic Advisor PIMCO “A variety of asset-backed securities have led to disruption around the world.” Bank of England, September 4, 2007 “Markets for a wide range of securities have de facto disappeared.” Financial Times, September 20, 2007 1 ”Practical men, who believe themselves to be quite exempt from any intellectual influence, are usually the slaves of some defunct economist.” John Maynard Keynes It is a truism to observe that financial markets clear at asset prices that balance the demand for reward against the supply of risk that is on offer at any point in time. Textbook models — even the most sophisticated, Nobel prize winning ones — typically begin with the assumption that there is a known underlying distribution from which asset returns are drawn. Given a fixed- and known-return distribution, investors can price options, identify relative values on yield curves, and decide on optimal hedge ratios for currencies. Of course, in practice the art of investing comes down to making informed judgments about distributions of returns that are not ‘known’ in advance. Indeed, getting the ex ante distribution of returns right is often the most important element of successful ‘risk’ manage- ment in actual financial markets, where the distribution of returns is an equilibrium outcome, not a preordained physical constant. However, under certain circumstances, it is crucially important to distinguish between the risk of undertaking an investment and the possibility of substantial uncertainty regarding the range of possible distributions of investment outcomes that an investor may confront. -
Second Quarter Hedge Fund of Funds Performance Report As of June 30, 2010
3. Presentation by Pension Consulting Alliance, Inc. - Second Quarter Hedge Fund of Funds Performance Report as of June 30, 2010 3 Water and Power Employees’ Retirement Plan (WPERP) Hedge Fund of Funds Investment Portfolio Quarterly Report Executive Summary This report is solely for the use of client personnel. No part of it may be circulated, quoted, or reproduced for distribution outside the client organization without prior written approval from Pension Consulting Alliance, Inc. Nothing herein is intended to serve as investment advice, a recommendation of any particular investment or type of investment, a suggestion of the merits of purchasing or selling securities, or an invitation or inducement to engage in investment activity. Pension Consulting Alliance Inc J 2010 Quarterly Report Q2-10 HEDGE FUND OF FUNDS PORTFOLIO SUMMARY As of June 30, 2010, the WPERP Hedge Fund of Funds Portfolio had an aggregate value of $70.0 million. Recent Investment Performance Trends During the most recent quarter, the WPERP Hedge Fund of Funds Portfolio underperformed its policy benchmark by minus (2.3%), net of fees. Over the latest 1-year period, the portfolio outperformed its benchmark by 6.7%, net of fees. The Portfolio trailed its policy benchmark over the latest 3-year time period. Underperformance over longer time periods can be attributed to severe market corrections in the second half of 2008. However, due to a strong 2009-2010, longer-term performance has improved significantly. Since inception, portfolio performance has been positive, resulting in no principal loss. The Total Portfolio surpassed the Median Fund over all time periods. The WPERP portfolio added significant value over the Median Fund since inception, outperforming 3.4%, net of fees. -
The Global Securitized Debt Market Opportunities Often Reside in the Debris of Crisis
Brandywine Global Investment Management, LLC Topical Insight | May 23, 2014 The Global Securitized Debt Market Opportunities Often Reside in the Debris of Crisis New issuance of private-label securitizations remains at nearly non-existent levels today despite more than five years of improving investor risk appetite since the Financial Crisis. While other spread- product markets reclaimed considerable new issuance momentum shortly after 2008, many investors today are still scarred from the miserable failures of private-label securitization during the housing crisis. Convolutedly packaged collateralized debt obligations (CDOs), backed by poorly underwritten subprime collateral, not only delivered steep price declines during the Financial Crisis, but market liquidity dried up quickly which impeded investors from exiting positions at reasonable valuations. Despite recent price gains in legacy securitized issues—those issued prior to 2008—neither the economics nor the tarnished reputation of securitization will justify a vigorous rebirth of the private- label new issue market anytime soon. As a result of the slowdown in new issuance and investors’ past trouble with these complex securities, many are choosing to fully avoid the legacy securitized market—eschewing exposure to both the private-label market and the more complex areas of the government-securitized market, called “agencies.” For that reason a large, under-owned, and under- followed collection of legacy securitized issues are available at attractive valuations. The legacy securitized market exhibits many of the inefficiencies that exemplify a distressed market. Those inefficiencies include all kinds of dislocations in the form of rating disparities, pricing anomalies, information asymmetry, ongoing regulatory uncertainties, unresolved legal settlements, abnormal servicer behavior, and an unclear future for housing finance. -
Media Physicians Public
TOP MOST-SHARED U.S. ARTICLES ON DRUG PRICING VIA TWITTER, AUG ‘15 – AUG ‘16 MEDIA PHYSICIANS PUBLIC 1. WSJ: “Why The U.S. 1. NYT: “Valeant’s Drug Price 1. NBC News: “EpiPen Price Pays More Than Other Strategy Enriches It, But Hike Has Parents Of Kids Countries For Drugs” Infuriates Patients And With Allergies Scrambling (12/1/15) Lawmakers” (10/4/15) Ahead Of School Year” (8/17/16) 2. WSJ: “How Pfizer Set The 2. NBC News: “EpiPen Price Cost Of Its New Drug At Hike Has Parents Of Kids 2. NYT: “Drug Goes From $9,850 A Month” (12/9/15) With Allergies Scrambling $13.50 A Tablet To $750, Ahead Of School Year” Overnight” (9/20/15) 3. NYT: “Valeant’s Drug Price (8/17/16) Strategy Enriches It, But 3. AP: “Breakthrough Infuriates Patients And 3. NYT: “Martin Shkreli’s Cholesterol Drugs Fizzle Lawmakers” (10/4/15) Latest Plan To Sharply Amid Price Pushback” Raise Drug Price Prompts (4/20/16) 4. WSJ:: “For Prescription Outcry” (12/11/15) Drug Makers, Price 4. USAT: “Company Hikes Increases Drive Revenue” 4. WaPo: “This Drug Is Price 5,000% For Drug (10/5/15) Defying A Rare Form Of That Fights Complication Leukemia — And It Keeps Of AIDS, Cancer” (9/18/15) 5. NYT: “Martin Shkreli’s Getting Pricier” (3/9/16) Latest Plan To Sharply 5. CBS: “Rising Cost Of Raise Drug Price Prompts 5. WSJ: “Why The U.S. Potentially Life-Saving Outcry” (12/11/15) Pays More Than Other EpiPen Puts Pinch On Countries For Drugs” Families” (8/16/16) 6.